RYM 8-K
RYTHM, Inc. (RYM)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Conditions.
On May 11, 2022, Agrify Corporation (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2022. A copy of the release is attached as Exhibit 99.1.
The information furnished herein, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.
Item 7.01. Regulation FD Disclosure.
The Company hereby furnishes the updated investor presentation attached as Exhibit 99.2 to this Current Report on Form 8-K, which the Company may use in presentations to investors from time to time.
The information furnished pursuant to this Item 7.01, including Exhibit 99.2, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. |
Description | |
| 99.1 | Press release issued by Agrify Corporation, dated May 11, 2022 | |
| 99.2 | Presentation of Agrify Corporation, dated May 11, 2022 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AGRIFY CORPORATION | ||
| Date: May 11, 2022 | By: | /s/ Timothy R. Oakes |
| Timothy R. Oakes | ||
| Chief Financial Officer | ||
2
Exhibit 99.1
Agrify Announces Record Revenue Results for First Quarter 2022
First Quarter Revenue Grew 271% Year-Over-Year to $26 Million, Exceeding Prior Guidance
First Quarter Contractual Backlog Increased by $77 Million
BILLERICA, Mass., May 11, 2022 - Agrify™ Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), the most innovative provider of advanced cultivation and extraction solutions for the cannabis industry, today announced financial results for the first quarter ended March 31, 2022.
“Increased customer adoption across our product lines not only fueled our Q1 growth but also helped strengthen the foundation for future high-margin recurring revenue streams, which we expect to begin to realize later this year,” said Raymond Chang, Chairman and Chief Executive Officer of Agrify. “We continue to make tremendous progress on the successful execution of our growth strategy as we expand our Vertical Farming Units (“VFUs”) and extraction customer base, selectively enter new limited-license states and international markets, and innovate and improve our product offerings.”
First Quarter 2022 Financial Results
| ● | Revenue was $26.0 million for the first quarter, an increase of 271% compared to $7.0 million for the prior year period. |
| ● | Gross profit for the first quarter totaled $4.2 million, or 16.0% of revenue, compared to $(540) thousand, or (7.7)% of revenue, in the prior year period. |
| ● | Operating expenses were $13.9 million for the first quarter, compared to $6.0 million in the prior year period. The comparative increase in the first quarter operating expenses is largely attributable to overall growth in the scale of the Company’s core business and recent acquisitions, increases in amortization expense associated with the intangible assets identified as part of the Company’s recently completed acquisitions, direct acquisition-related costs, an investment banker termination fee, and restructuring charges. |
| ● | Net loss for the first quarter was $8.9 million, or $0.36 per diluted share, compared to net loss of $3.8 million, or $0.33 per diluted share, in the prior year period. |
| ● | Cash flow used in operating activities was $34.2 million for the first quarter, compared to $7.3 million in the prior year period. First quarter 2022 cash flows used in operating activities related to the increase in inventory associated with the current and future construction of the Company’s VFUs, current quarter operating performance, first quarter renewals of insurance policies, and the capitalization of debt issuance costs. |
| ● | Adjusted EBITDA (a non-GAAP financial measure) was a loss of $6.1 million in the first quarter (see “Non-GAAP Financial Measures” below for further discussion of this non-GAAP term, including a reconciliation to the most comparable GAAP measure), compared to a loss of $4.2 million in the prior year period. |
Recent Business Highlights
| ● | On May 10, 2022, Agrify announced a $2 million agreement with Michigan-based Boone Labs to outfit its new production facility with the complete range of Agrify offerings including 72 VFUs powered by the Agrify Insights™ software, as well as solventless extraction, hydrocarbon extraction, and ice water hash washing solutions. Boone Labs will be the first customer to leverage Agrify’s full suite of offerings, across cultivation, extraction, and consumer brands, to create a fully operational cannabis production business. |
| ● | On May 6, 2022, Agrify announced the launch of the PX5 product from its Extraction Division, expanding its portfolio of industry-leading processing solutions with its latest, most advanced and scalable passive hydrocarbon extractor. The PX5’s unique passive recovery design offers immediate economic benefits to cannabis operators of any size with projected benefits including an increase in daily production of up to 33%, savings in annual energy costs of up to 40%, and an increase in hourly extract production of 200% to 300% with specialized training available from Agrify Extraction. |
| ● | On April 20, 2022, Agrify announced the launch of its VFU Rapid Deployment Packs, which allow cultivators to accelerate their speed to market and streamline VFU adoption for multi-state operators (“MSOs”) without requiring major building renovations that cause disruptions to existing operations. |
| ● | On April 13, 2022, Agrify announced its VFU sales agreement with BioCann Pharmaceutical, a prominent cannabis cultivator in Madeira, Portugal. The agreement will introduce the Company’s VFU technology into Europe, one of the largest cannabis markets in the world with high and stringent quality and safety requirements. The agreement includes the purchase of 190 VFUs and $2.3 million in estimated SaaS fees. |
| ● | On April 11, 2022, Agrify announced it had entered into an Agrify Total Turn-Key Solution (“Agrify TTK Solution”) partnership with Loud Wellness, a licensed New Jersey-based cultivation and manufacturing operator. The partnership, which includes the installation of 500 VFUs, is expected to generate approximately $118 million of estimated total revenue for Agrify over the full 10-year term of the agreement, of which $100 million is estimated to be from production success fees and $18 million is estimated to be from SaaS fees. |
| ● | On April 6, 2022, Agrify announced its VFU sales agreement with Greenlight Cannabis (“Greenlight”), a prominent and rapidly growing MSO in the United States with 28 locations across 5 states. Under the agreement, the Company plans to install VFUs that will enable Greenlight to increase its grow canopy in order to achieve rapid business growth and geographic expansion under one standard. |
About Agrify TTK Solution
The Agrify TTK Solution is a first-of-its-kind program in which Agrify engages with qualified cannabis operators in the early phases of their business and provides critical support, typically over a 10-year period, which includes: design and buildout of their cultivation and extraction facilities, state-of-the-art cultivation and extraction equipment, process design, training, implementation, proven grow recipes, product formulations, data analytics, and consumer branding.
VFU Backlog
Agrify currently has contractual commitments for 4,569 VFUs that will be powered by the Agrify Insights cultivation and production software. 3,783 of these VFUs were committed to as part of the Agrify TTK Solution, which requires customers to pay production success fees and SaaS fees for up to a 10-year period, and it also typically includes Agrify providing a variety of other value-added services. The remaining 786 VFUs were sold to customers through onetime equipment sales that require theses customer to pay monthly SaaS fees (per VFU). Cumulatively, all of the VFUs under Agrify TTK Solution agreements or SaaS agreements are estimated to produce approximately $923 million in total revenue over the next 10 years, of which $674 million is in anticipated high-margin production success fees, $129 million is in anticipated high-margin SaaS fees, and $95 million is in construction-related fees.
2
2022 Outlook
Agrify reiterates its previously provided revenue guidance for Fiscal Year 2022 to be in the range of $140 million to $142 million.
Conference Call and Webcast Information
Agrify will host a conference call and webcast today (Wednesday, May 11, 2022) at 8:30 a.m. Eastern Time (ET) to discuss its financial results for the first quarter ended March 31, 2022.
All interested parties are invited to listen to the live conference call by dialing the number below or by clicking the webcast link, which can be accessed by visiting Agrify’s Investor Relations website at ir.agrify.com and navigating to the Events page. The Company has also posted an accompanying slide presentation, which can be found in the same location as the webcast link.
| ● | DATE: Wednesday, May 11, 2022 |
| ● | TIME: 8:30 a.m. ET |
| ● | WEBCAST (live and available for replay): https://ir.agrify.com/news-and-events/investor-calendar |
| ● | DIAL-IN NUMBER: (844) 792-4409 |
| ● | CONFERENCE ID: 2387725 |
About Agrify (Nasdaq:AGFY)
Agrify is the most innovative provider of advanced cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. Our proprietary micro-environment-controlled Vertical Farming Units (VFUs) enable cultivators to produce the highest quality products with unmatched consistency, yield, and ROI at scale. Our comprehensive extraction product line, which includes hydrocarbon, ethanol, solventless, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates. For more information, please visit Agrify at http://www.agrify.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Agrify and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding future financial results, including expected revenue, integration of prior acquisitions, the timing and ability to launch new products, the ability to realize revenue from the bookings, backlog, pipeline and specific transactions described herein, the revenue expected from any Agrify TTK Solution transactions and the duration of those revenue streams, project timelines, and Agrify’s ability to deliver solutions and services. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including those described in our filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in our Annual Report on Form 10-K filed for the year ended December 31, 2021 with the SEC, which can be obtained on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the SEC.
3
AGRIFY CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statement of Operations
(In thousands, except for per share amounts)
(Unaudited)
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Revenue | $ | 26,021 | $ | 7,008 | ||||
| Cost of goods sold | 21,851 | 7,548 | ||||||
| Gross profit | 4,170 | (540 | ) | |||||
| General and administrative | 9,759 | 4,458 | ||||||
| Sales and marketing | 2,090 | 616 | ||||||
| Research and development | 2,084 | 882 | ||||||
| Total operating expenses | 13,933 | 5,956 | ||||||
| Loss from operations | (9,763 | ) | (6,496 | ) | ||||
| Interest income (expense), net | 682 | (32 | ) | |||||
| Gain on extinguishment of notes payable | - | 2,685 | ||||||
| Other income, net | 682 | 2,653 | ||||||
| Net loss before income taxes | (9,081 | ) | (3,843 | ) | ||||
| Income tax benefit | (200 | ) | - | |||||
| Net loss | (8,881 | ) | (3,843 | ) | ||||
| Income (loss) attributable to non-controlling interest | 1 | (33 | ) | |||||
| Net loss attributable to Agrify | $ | (8,882 | ) | $ | (3,810 | ) | ||
| Net loss per share attributable to common | ||||||||
| stockholders – basic and diluted | $ | (0.36 | ) | $ | (0.33 | ) | ||
| Weighted average commons shares | ||||||||
| outstanding – basic and diluted | 24,589 | 11,568 | ||||||
4
AGRIFY CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | (Audited) | |||||||
| Cash and cash equivalents | $ | 25,205 | $ | 12,014 | ||||
| Restricted cash | 30,000 | - | ||||||
| Marketable securities | 38,211 | 44,550 | ||||||
| Accounts receivable, net | 8,571 | 7,222 | ||||||
| Inventory | 38,989 | 20,498 | ||||||
| Prepaid expenses and other assets | 6,567 | 2,452 | ||||||
| Total current assets | 147,543 | 86,736 | ||||||
| Loan receivable, net | 34,738 | 22,255 | ||||||
| Property and equipment, net | 7,055 | 6,232 | ||||||
| Right-of-use assets, net | 1,554 | 1,479 | ||||||
| Goodwill and intangible assets, net | 70,405 | 64,162 | ||||||
| Other non-current assets | 3,180 | 1,184 | ||||||
| Total assets | $ | 264,475 | $ | 182,048 | ||||
| Liabilities | ||||||||
| Accounts payable | $ | 3,683 | $ | 9,151 | ||||
| Accrued expenses and other current liabilities | 30,112 | 28,764 | ||||||
| Operating lease liabilities, current | 911 | 814 | ||||||
| Long-term debt, current | 2,970 | 1,089 | ||||||
| Deferred revenue | 4,182 | 3,772 | ||||||
| Total current liabilities | 41,858 | 43,590 | ||||||
| Other non-current liabilities | 275 | 318 | ||||||
| Deferred tax liabilities, net | 62 | - | ||||||
| Operating lease liabilities, non-current | 689 | 704 | ||||||
| Long-term debt | 51,154 | 12 | ||||||
| Total liabilities | 94,038 | 44,624 | ||||||
| Stockholders’ Equity | ||||||||
| Common stock | 25 | 21 | ||||||
| Preferred stock | - | - | ||||||
| Additional paid-in capital | 237,903 | 196,013 | ||||||
| Accumulated deficit | (67,857 | ) | (58,975 | ) | ||||
| Total stockholders’ equity | 170,071 | 137,059 | ||||||
| Non-controlling interests | 366 | 365 | ||||||
| Total liabilities and stockholders’ equity | $ | 264,475 | $ | 182,048 | ||||
5
AGRIFY CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)
| Three Months Ended March 31, |
||||||||
| 2022 | 2021 | |||||||
| Cash flow (used in) provided by: | ||||||||
| Operating activities | $ | (34,171 | ) | $ | (7,279 | ) | ||
| Investing activities | (13,365 | ) | (142 | ) | ||||
| Financing activities | 90,727 | 137,197 | ||||||
| Net increase in cash, cash equivalents and restricted cash | $ | 43,191 | $ | 129,776 | ||||
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use Adjusted EBITDA, which is a non-U.S. GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of Adjusted EBITDA enhances an investor’s understanding of our financial performance. We further believe that Adjusted EBITDA is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes, measuring our performance relative to that of our competitors and determining our compliance with certain debt instruments. We utilize Adjusted EBITDA as a key measure of our performance.
We calculate Adjusted EBITDA as net loss adjusted to exclude (i) tax provision and benefit; (ii) interest income and expense, net; (iii) other income and expense, net; (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) acquisition-related expenses; (vii) investment banker termination fees; (viii) restructuring charges; (ix) gains and losses associated with the extinguishment of debt; (x) changes in derivative liabilities; (xi) changes in contingent consideration; (xii) gain associated with the forgiveness of PPP loans; and (xiii) other items affecting our results that we do not view as representative of our ongoing operations, including losses associated with write-offs.
We believe Adjusted EBITDA is a commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term Adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.
Adjusted EBITDA has important limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. Our public offering and acquisition-related expenses, including legal, accounting and other professional expenses, reflect cash expenditures and we expect such expenditures to recur from time-to-time. Our Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate Adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure.
6
In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered as an alternative to loss before benefit from income taxes, net loss, earnings per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.
The following table presents a reconciliation of Adjusted EBITDA from the most comparable GAAP measure, net loss, for the three months ended March 31, 2022 and 2021:
AGRIFY CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA
(In thousands)
(Unaudited)
| Three Months Ended March 31, |
||||||||
| 2022 | 2021 | |||||||
| Net loss | $ | (8,882 | ) | $ | (3,810 | ) | ||
| Add: | ||||||||
| Income tax benefit | (200 | ) | - | |||||
| Interest (income) expense | (682 | ) | 32 | |||||
| Depreciation and amortization | 1,052 | 147 | ||||||
| Stock-based compensation | 953 | 2,135 | ||||||
| Direct acquisition expenses | 637 | - | ||||||
| Investment banker termination fees | 637 | - | ||||||
| Restructuring charges | 387 | - | ||||||
| Gain on extinguishment of notes payable | - | (2,685 | ) | |||||
| Adjusted EBITDA | $ | (6,098 | ) | $ | (4,181 | ) | ||
Company Contacts
Agrify
Timothy Oakes
Chief Financial Officer
(781) 760-7512
Investor Relations Inquiries
Anna Kate Heller
ICR
Media Inquiries
Justin Bernstein
MATTIO Communications
7
Exhibit 99.2
Passionately Transforming Cannabis Through Innovation Q122 Earnings Call May 11, 2022
2 Passionately Transforming Cannabis Through Innovation Important Notices & Disclosures This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, our ability to realize revenue from the bookings, backlog, pipeline and transactions described herein, the revenue expected from any Agrify TTK Solutions transaction s, projected costs, prospects, plans, customers, objectives of management and expected market growth are forward - looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward - looking statements. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may, " "plan," "potential," "predict," "project, " " should," 'target," "will, " "would" and similar expressions are intended to identify forward - looking statements, although not all forward - looking statements contain these identifying words. These forward - looking statements are only predictio ns and we may not actually achieve the plans, intentions or expectations disclosed in our forward - looking statements, so you should not place undue reliance on our forward - looking statements. Actual results or events could dif fer materially from the plans, intentions and expectations disclosed in the forward - looking statements we make. We have based these forward - looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in our Annual Report on Form 10 - K fo r the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission ("SEC") and our other filings with the SEC. You may access these documents for free by visiting EDGAR on the SEC website at http://ww w.s ec.gov. Forward - looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information except as required under applicable law. The forward - looking statements included in this presentation represent our views as of the date of this presentation. We anticip ate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward - looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward - looking statements as representing our views as of any date subsequent to the date of this presentation. This presentation contains estimates made, and other statistical data published, by independent parties and by us relating to ma rket size and growth and other data about our industry. We obtained the industry and market data in this presentation from our own research as well as from industry and general publications, surveys and studies conducted by third par ties. This data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. W e c aution you not to give undue weight to such projections, assumptions and estimates. This presentation is for information purposes only and is being provided to you solely in your capacity as a potential invest or in considering an investment in Agrify Corporation (the "Company'). The information contained herein does not purport to be all - inclusive and neither the Company nor any of its directors, officers, stockholders or affiliates makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the Information contained in this presentation or any other written or oral communication communicated to the recipient in the co urs e of the recipient's evaluation of the Company or an investment in the securities. The information contained herein is preliminary and is subject to change and such changes may be material. This presentation does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase an y s ecurity of the Company. You should not construe the contents of this presentation as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and rel ated matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the Information contained herein to make any decision. No securities commission or securities regulatory authority in the United States or any other jurisdiction has in any way pas sed upon the merits of this presentation.
Q1’22 Review
4 4
5 5 • Extraction Division announces Multimillion dollar agreement with Boone Labs • First customer leveraging full suite of Agrify offerings • $1.5M for 72 VFUs in new 8500 sq. ft. facility • $500K for solventless & hydrocarbon extraction solutions • Extraction Division announces the launch of the PX5 • I ndustry - leading processing solutions with the latest, most advanced and scalable passive hydrocarbon extractor • P roviding increased daily production up to 33% and increasing hourly extract production by over 200%. • The launch of the VFU Rapid Deployment Packs • Pre - configured, quick to install VFU packages including 10 VFU’s, 15 VFU’s, 20 VFU’s, and 28 VFU’s • A ccelerating VFU’s speed to market and streamlining adoption with SSO and MSO’s.
$0 $5,000,000 $10,000,000 $15,000,000 $20,000,000 $25,000,000 $30,000,000 Q121 Q122 A 271% YoY Increase $26M $7M Q122 Revenue Growth (year over year) 6 Passionately Transforming Cannabis Through Innovation
Q122 New Bookings were $43M Marketing Excellence 5,119 new contacts YTD 43% 38% 9% 8% 2% Extraction Production Success Fees SaaS Fees VFU Purchase Other New Bookings Mix Note: New Bookings Represent Only 3 Years of Contractual Commitments 7 Passionately Transforming Cannabis Through Innovation
Q122 Financial Results Summary 8 Passionately Transforming Cannabis Through Innovation Revenue = $26.0M vs $7.0M in Q121 o $6.6M, or 94% YoY “organic” increase in revenue ($13.6M vs $7.0M) o TTK construction revenue - $13.2M o Extraction revenue - $12.4M (vs $12.2M in Q421) Gross Profit = $4.2M, Gross Margin of 16% o Extraction - 33% Gross Margin o Design and Build - 1% Gross Margin (vs 3% standard) o Unbillable work / Construction delay penalties / Overtime Operating Expenses =$13.9M in Q122 o Includes one - time charges: o Direct Acquisition Costs - $0.6M o Banker Termination Fees - $0.6M o Restructuring Costs - $0.4M o $12.3M Normalized Run Rate (with Depreciation, Amortization and SBC)
Q1'22 Q1'21 (In Thousands) Prelim Actual $$ %% Revenue 26,021$ 7,008$ 19,013$ 271.3% Cost of Goods Sold 21,851 7,548 14,303 189.5% Gross Profit 4,170 (540) 4,710 (872.2)% Gross Margin % 16.0% (7.7)% 23.7% Operating Expenses: G&A 9,759 4,458 5,301 118.9% Sales and Marketing 2,090 616 1,474 239.3% Research and Development 2,084 882 1,202 136.3% Total OpEx 13,933 5,956 7,977 133.9% Operating Loss (9,763) (6,496) (3,267) 50.3% Other Income (Expense): Interest Income (Expense), Net 682 (32) 714 (2231.3)% Gain on Extinguishment of Note Payable - 2,685 (2,685) (100.0)% Total Other Income, Net 682 2,653 (1,971) (74.3)% Income Before Taxes (9,081) (3,843) (5,238) 136.3% Income Tax Benefit (200) - (200) (100.0)% Net Loss (8,881) (3,843) (5,038) 131.1% Income (loss) Non-Controlling Interest 1 (33) 34 (103.0)% Net Loss (8,882)$ (3,810)$ (5,072)$ 133.1% YoY Change Q122 Preliminary Financial Results 9 Passionately Transforming Cannabis Through Innovation First Quarter 2022 Preliminary Financial Results: Q122 Prelim Q121 Actual YoY Change $ % Q122 Results vs Analyst Estimates: ▪ Revenue : Company Guidance: $25.5M ( above) Analyst Average: $25.4M ( above ) Consensus Estimate: $25.4M ( above ) ▪ Gross Profit / Margin % : Analyst Average: $4.0M / 15.7% ( above ) Consensus Estimate: $4.0M / 15.8% ( above ) ▪ S,G&A : Analyst Average: $10.9M ( above ) Q1’22 Impacts: Transaction Costs: $0.6M Investment Banker Termination: $0.6M Restructuring: $0.4M Adjusted S,G&A = $10.2M ( below ) ▪ Operating Expenses : Analyst Average: $12.1M ( above ) Adjusted for One - Time: $12.3M ( above ) ▪ Net Loss : Analyst Average: $8.7M ( above )
(In Thousands) Q1'22 Reconciliation of GAAP Net Income to Adjusted EBTIDA (Non-GAAP): Reported GAAP Net Loss (8,882)$ Income Tax Benefit (200) Interest Income, Net (682) Depreciation and Amortization 1,052 Stock-Based Compensation Expense 953 Direct Acquisition Costs 637 Investment Banker Termination Fees 637 Restructuring Charges 387 Adjusted EBITDA (6,098)$ Adj. EBITDA Per Share (0.25)$ Diluted Shares 24,589 Total Revenue 26,021$ Adj. EBITDA (as % of Revenue) (23.4)% Q122 Adjusted EBITDA (Non - GAAP Financial Measure) 10 Passionately Transforming Cannabis Through Innovation Q122 Adjusted EBITDA Loss: ▪ Compared to Analyst Estimates : Analyst Average: $(5.9)M ( above ) ▪ Compared to High Trail Debt Covenants : Q122 Debt Covenant: $(6.1)M ( AT ) In compliance with Q1’22 Debt Agreement Covenant Q222 Covenant Target: $(5.5)M Q122 We believe Adjusted EBITDA Is a commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term Adjusted EBITDA may vary from that or others in our Industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance wit h U .S. GAAP as measures of performance. Adjusted EBITDA has important limitations as an analytical tool and you should not consider it in isolation or as a substitut e f or analysis of our results as reported under U.S. GAAP. Some of the limitations of adjusted EBITDA Include ( i ) adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non - cash char ges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. Our publi c offering and acquisition - related expenses, including legal, accounting and other professional expenses, reflect cash expenditure s and we expect such expenditures to recur from time - to - time. Our Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate Adjusted EBITDA in the same manner as we calculate the measure, li mit ing its usefulness as a comparative measure.
Q122 Balance Sheet - Assets 11 Passionately Transforming Cannabis Through Innovation ▪ Cash/Marketable Securities/Restricted Cash : Combined balance of $93.4M (vs $66.5M as of December 31 st ). Reflects cash infusion of $27M from a private placement transaction and $65M from an initial draw against a debt facility. $30.0M, per debt facility agreement, is restricted, and not accessible to support Company operations. ▪ Inventory: First quarter increase represents the build in inventory associated with both VFU production schedules, the procurement on long lead items as a result of potential supply chain issues and initial deposits on inventory items with new contract manufacturers. ▪ Prepaid Expenses/Other : The increase represents the Company’s renewal of annual insurance policies (D&O, etc.) in the first quarter of 2022. ▪ Loans Receivable : Balance represents advances under TTK financing / construction contracts. All projects, as of March 31, 2022 are in “build phase,” however several construction projects will begin to come online (i.e. complete construction phase) in Q222. ▪ Goodwill and Intangibles : YoY change represents the Company’s acquisition of Lab Society during the first quarter of 2022. The measurement period of the Pure Pressure and Lab Society acquisitions remain open as of March 31, 2022. March 31, December 31, 2022 2021 ASSETS: Cash and Cash Equivalents 25,205$ 12,014$ Retricted Cash 30,000 0 Marketable Securities 38,211 44,550 Accounts Receivable 8,571 7,222 Inventory 38,989 20,498 Prepaid Expenses and Other 6,567 2,452 Total Current Assets 147,543 86,736 Loans Receivable 34,738 22,255 Property and Equipment 7,055 6,232 Right of Use Assets 1,554 1,479 Goodwill and Intangible Assets 70,405 64,162 Other Assets 3,180 1,184 Total Assets 264,475$ 182,048$ (Unaudited) (Audited)
Q122 Balance Sheet - Liabilities 12 Passionately Transforming Cannabis Through Innovation ▪ Accounts Payable : Decrease in AP relates to the first quarter payment of acquired accounts payable balances associated with acquisition, TTK project related payments, etc. in the first quarter of 2022. ▪ Accrued Expenses : Accrued expense balances include accruals associated with acquisition - related liabilities (estimated FV of contingent consideration and FV of shares held - back), sales and use taxes, TTK - related construction costs and compensation - related amounts. ▪ Current/Long Term Debt : The increase in the debt - related balance sheet accounts relates to the net value of the Company’s initial funding ($65.0M) under a debt facility arrangement. March 31, December 31, 2022 2021 LIABILITIES Accounts Payable 3,683$ 9,151$ Accrued Expenses 30,112 28,764 Lease Liabilities, Current 911 814 Long-Term Debt, Current 2,970 1,089 Deferred Revenue 4,182 3,772 Total Current Liabilities 41,858 43,590 Deferred Tax Liabilities 62 0 Other Non-Currnet Liabilities 275 318 Lease Liabilities, Non-Current 689 704 Long-Term Debt 51,154 12 Total Liabilities 94,038$ 44,624$ (In Thousands) (Unaudited) (Audited)
Q122 Balance Sheet – Stockholders Equity 13 Passionately Transforming Cannabis Through Innovation ▪ Common Stock/APIC : Increase is related to current year equity - based activities: ▪ Issuance of shares and warrants in connection with the January 2022 private placement ▪ Issuance of warrants in connection with the March 2022 debt facility arrangement ▪ Q122 Warrant Exercises ▪ Recognition of Stock - Based Compensation ▪ Accumulated Deficit : Change is solely reflective of the current quarter ($8.9)M loss from operations (Unaudited) (Audited) March 31, December 31, 2022 2021 STOCKHOLDERS' EQUITY Common Stock 25$ 21$ Preferred Stock 0 0 Preferred Stock - Class A 0 0 Additional Paid-In Capital 237,903 196,013 Accumulated Deficit (67,857) (58,975) Total Stockholders' Equity 170,071 137,059 Non-Controlling Interests 366 365 Total Liabilities and Stockholders' Equity 264,475$ 182,048$ (In Thousands)
▪ Operating Activities : Cash flow usage is primarily associated with the reported net operating loss in Q122 ($(8.9)M, and inventory build of approximately $(16.0)M and the renewal of current year insurance policies (D&O, etc.) and the capitalization of debt issuance costs. ▪ Investing Activities : Usage of cash in Q122 reflects the increase in loans receivable associated with out TTK construction projects, purchases of property and equipment, the cash paid for the acquisition of Lab Society, which were offset by net redemptions of marketable securities. ▪ Financing Activities : Net cash provided by financing activities related to the net proceeds received by the Company in connection with the January 2022 private placement and the $65.0M in debt financing associated with the initial draw under the debt facility arrangement. ▪ Summary : Overall, in the first quarter of 2022, the Company raised approximately $90.7M in capital which will be deployed to continue to drive top line revenue growth as well as to fund existing construction and VFU production costs associated with our TTK arrangements. March 31, March 31, Net Cash (Used In) Provided By: 2022 2021 Operating Activities (34,171)$ (7,279)$ Investing Activities (13,365) (142) Financing Activities 90,727 137,197 Net Increase in Cash 43,191 129,776 Cash/Restricted Cash - Beginning of Period 12,014 8,111 Cash/Restricted Cash - End of Period 55,205$ 137,887$ (In Thousands) Amounts March 31, 2022: (In Thousands) Cash and Cash Equivalents 25,205$ Restricted Cash 30,000 Marketable Securities 38,211 Total Available Cash/Securities 93,416$ (Unaudited) (Unaudited) Q122 Cash Flow (Condensed Summary) 14 Passionately Transforming Cannabis Through Innovation Amounts
VFU Backlog & Project Status
16 Passionately Transforming Cannabis Through Innovation 11 # of ENGAGEMENTS TTK & NON - TTK 4,569 TOTAL VFUs UNDER CONTRACT $84M ** ANNUAL RECURRING REVENUE $923M TOTAL 10 YEAR CONTRACTUAL BACKLOG 160K * POUNDS PER YEAR Total VFU Engagements Impact ** Estimated annual recurring revenue will be from high - margin SaaS fees and production success * Estimated pounds per year is based on each VFU producing 35 pounds of cannabis flower annually Estimated Projections fees, once all 4,569 VFUs are commissioned and averaging 7 pounds per harvest
17 Passionately Transforming Cannabis Through Innovation $923M of Contractual Backlog Mix 70% 14% 10% 2% 2% 1% 1% Production Success Fees SaaS Fees Design & Build Interest (Build) Extraction Interest (VFU) VFU Purchase Production Success Fees SaaS Design & Build Interest (Build) Extraction VFU Interest Estimated Projections
18 18 In Agrify’s business model, average 7 per harvest 34 %
19 Passionately Transforming Cannabis Through Innovation VFU Project Status Updates Customer State VFUs Commissioning First Harvest > TTK ( production success fees & monthly SaaS fees) # of Projected Initial Projected > VFU Sales (monthly SaaS fees) Greenstone CO 239 Q222 Q322 Treehouse NV 132 Q222 Q322 Hannah WA 186 Q222 Q322 True House MA 159 Q223 Q323 Kief USA MA 485 Q223 Q323 Bud & Mary’s MA 572 Q422 Q223 Gold Leaf FL 1,510 Q323 Q423 Loud Wellness NJ 500 Q223 Q323 WhiteCloud NV 196 Q222 Q322 El Mirage AZ 400 Q223 Q223 BioCann Portugal 190 Q123 Q223
FY 2022 Revenue Projections
FY 2022 Revenue Projections NOTE: Agrify projects more than 60% of the projected 2022 revenue will be in the second half of the fiscal year. 21 Passionately Transforming Cannabis Through Innovation A 134% YoY Increase $0 $20 $40 $60 $80 $100 $120 $140 2021 2022 FULL YEAR REVENUE (M)